Japan Structural Heart Devices Market: By Procedure (Repair (Annuloplasty, Valvuloplasty, Transcatheter Mitral Valve Repair (TMVR), and Others) Replacement (Surgical Valve, Mechanical Heart Valve, Tissue Heart Valve, and Transcatheter Aortic Valve Replacement (TAVR), By Position (Aorta, Mitral, Pulmonary valve, and Tricuspid valve), By Product (Heart Valve Devices, Occluders Delivery Systems, Annuloplasty Rings, and Others) and Country

The japan structural heart devices market size was valued at US$ 693.2 million in 2023 and is projected to reach a value of US$ 1,756.0 million by 2030, at a CAGR of 14.2% from 2024-2030.

The market is driven by factors such as the rising prevalence of cardiovascular diseases, minimally invasive procedures, favorable reimbursement scenarios, and growing awareness. Heart disease is a major killer, and the incidence of these conditions is expected to rise due to an aging population and increasing risk factors like obesity and diabetes. This creates a larger patient pool needing treatment. Structural heart devices enable minimally invasive procedures like transcatheter aortic valve replacement (TAVR), which offer quicker recovery times and less patient discomfort compared to open-heart surgery. This shift towards minimally invasive treatments is a major growth factor.

Key Players

Key players include Medtronic, Edwards Lifesciences, Boston Scientific, Abbott Laboratories, LivaNova, Terumo Corporation, JenaValve Technology, Avinger, MedeAnalytics, Ramsay Santé. Also, a comprehensive analysis of industry verticals and market participants that provides a clear overview of the competitive landscape in relation to the sectors served by the company’s products and services, market share, service offerings, financial reports, significant developments, market strategy, competitive position, and geographic reach.

Key Takeaways

• Based on the procedure, the replacement segment holds a 63.7% market share
• Based on the position mitral segment holds a 39.6% market share
• Based on the Product Heart Valve Devices segment holds a 28.5% market share
• As of 2022, around 70% of heart valve procedures in Japan were performed using minimally invasive techniques, reflecting a shift in surgical practices
• In 2021, Japanese medical device companies invested approximately ¥120 billion (about $1.1 billion) in research and development for structural heart technologies

Facts & Figures

• In 2022, approximately 15,000 Transcatheter Aortic Valve Replacement (TAVR) procedures were performed in Japan.
• As of March 2023, heart valve devices accounted for about 65% of the total structural heart device market in Japan
• In January 2023, the Pharmaceuticals and Medical Devices Agency (PMDA) approved three new heart valve devices for market entry in Japan

Key Developments

• In June 2023, Medtronic launched its latest transcatheter aortic valve replacement (TAVR) device in Japan, enhancing treatment options for aortic stenosis.
• In March 2023, Edwards received approval for its next-generation transcatheter heart valve, expanding its portfolio in the Japanese market.
• In September 2022, Boston Scientific announced the successful completion of its first procedures using a new left atrial appendage closure device in Japan

 Japan Structural Heart Devices Market Segmentation

By Procedure: Replacement is the largest segment in the market and is picking up with the popularity of TAVR procedures. The benefits of the least-invasive techniques and the higher prevalence of an aging population with aortic stenosis are doing well for this segment. Though surgical and tissue heart valves also contribute to the market widely, the popularity of TAVR is considerably aiding market growth in general.

By Position: The Aorta segment will lead in the Japan Structural Heart Devices Market, primarily due to the increase in the adoption of Transcatheter Aortic Valve Replacement (TAVR) procedures. The technological advancements along with increasing valve disorders in the geriatric population will further widen this segment. The Mitral valve segment will share significant market space in Japan primarily due to the growing adoption of minimally invasive procedures such as Transcatheter Mitral Valve Repair (TMVR). The Pulmonary and Tricuspid valve segments, though important, are smaller portions of the current market compared with the Aorta and Mitral segments.

By Product: The Heart Valve Devices segment is a market leader within Japan's Structural Heart Devices, with the activity fuelled by trends associated with both transcatheter use, mostly for aortic valve procedures, and surgical valves, largely for mitral valve procedures. The category is boosted by continued technological improvements and volumes of more procedures. The Occluders Delivery Systems segment also grows strongly, following similar patterns as increases in the use of devices to address conditions, including atrial septal defects.